

**Supplemental Table 3. Multivariable binary logistic regression analyses of the association of change in PON1 activity with individual ACR 20/50/70 treatment responses.**

Total Cohort N=1029	ACR20	ACR50	ACR70
<b>PON<sup>#</sup></b>	1.10 (0.98, 1.22)	1.16 (1.02, 1.32)*	1.14 (0.96, 1.35)
<b>LAC<sup>#</sup></b>	1.13 (1.04, 1.23)*	1.12 (1.02, 1.23)*	1.15 (1.01, 1.30)*
<b>ARYL<sup>#</sup></b>	1.13 (1.04, 1.24)*	1.09 (0.98, 1.21)	1.21 (1.05, 1.39)*
<b>Adjusted Model (Additionally Controlling for Percent Change in HDL)</b>			
<b>PON<sup>#</sup></b>	1.06 (0.95, 1.18)	1.14 (1.00, 1.29)	1.13 (0.95, 1.34)
<b>LAC<sup>#</sup></b>	1.11 (1.02, 1.21)*	1.10 (1.00, 1.21)	1.13 (1.00, 1.29)
<b>ARYL<sup>#</sup></b>	1.11 (1.02, 1.22)*	1.07 (0.97, 1.19)	1.20 (1.04, 1.38)*

\*p<0.05

Values are OR (95% CI).

Model adjusted for BMI, RA disease duration, seropositivity. Interaction terms for PON1 activity and drug group were not significant for ACR 20, 50, or 70 (all P>0.1)

<sup>#</sup>X (X=PON, LAC, ARYL) values are difference in log<sub>10</sub>X from 0 to 6 months. Units are Log(U/mL).

PON=paraoxonase; LAC=lactonase; ARYL=arylesterase; TNFi=tumor necrosis factor inhibitor;

RTX=rituximab; ABA=abatacept; TCZ=tocilizumab